The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(4), 613-628 (2025)
- Authors:
- Elnaggar, Mohamed, Mansinho, Joana Nunes, Malkin, Samuel J P, Whitaker, Joseph, Hunt, Barnaby, Glah, Divina, MacLellan, Martina, Ali, Samina
- Database ID:
- RPEP-10845
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10845APA
Elnaggar, Mohamed; Mansinho, Joana Nunes; Malkin, Samuel J P; Whitaker, Joseph; Hunt, Barnaby; Glah, Divina; MacLellan, Martina; Ali, Samina. (2025). The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(4), 613-628. https://doi.org/10.1007/s13300-025-01691-1
MLA
Elnaggar, Mohamed, et al. "The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.." Diabetes therapy : research, 2025. https://doi.org/10.1007/s13300-025-01691-1
RethinkPeptides
RethinkPeptides Research Database. "The Long-Term Cost-Effectiveness of Oral Semaglutide Versus ..." RPEP-10845. Retrieved from https://rethinkpeptides.com/research/elnaggar-2025-the-longterm-costeffectiveness-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.